News

Nuvation Bio wins FDA sNDA for Ibtrozi with nearly four-year duration of response in ROS1+ lung cancer

What's the deal? On 16 September 2026, Nuvation Bio said the US Food and Drug Administration (FDA) approved a supplemental new drug application for Ibtrozi (taletrectinib), its once-daily pill for locally advanced or metastatic ROS1-positive non-small cell lung cancer — a form of lung cancer driven by a change in the ROS1 gene. The updated label now includes a median duration of response of 49.7 months (just over four years) in people in the TRUST-I study who had not previously received a tyrosine kinase inhibitor (TKI), a targeted cancer pill. Nuvation said this is the longest median duration of response reported for an FDA-approved ROS1 TKI. The approval came four months ahead of the FDA's target decision date. There were no changes to the safety sections of the label and no new safety signals with longer follow-up.

Why it matters: Duration of response is how long a tumour keeps shrinking or staying controlled after treatment starts. Putting nearly four years of benefit on the official label gives doctors and patients a clearer picture of how long Ibtrozi may work when used early. The filing used a median 51 months of follow-up from TRUST-I and an extra 14 months of data from both TRUST-I and TRUST-II, cut off in August 2025. Many patients stayed on treatment for years with a continued response. The longer-term data were presented at the American Association for Cancer Research annual meeting in 2026 and published in the Journal of Clinical Oncology . Ibtrozi is also approved in Japan (Nippon Kayaku) and China.

Read more: Nuvation Bio / PR Newswire, 16 September 2026

More top stories